Alvotech ALVO
Set alert
As of Nov 3, 2:24 PM ET
- YTD
- -11.01%
- 1 year
- -9.24%
- Open
- 4.49
- Prev close
- 4.48
- Mkt cap
- 1.63B
- Vol
- 259.96K
- Avg vol
- 1.05M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 4.48
- High
- 4.65
- Forward P/E
- 19.47
- Beta
- 0.24
- Short ratio
- 4.72
- Inst. own
- 12.82%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 11, 2026
- 50-d avg
- 5.32
- 200-d avg
- 4.21
- 1y target
- 7.20
5D chart
Signals (72)
| Name | Time | Ago |
|---|---|---|
| SMA: Bullish | Nov 3, 1:35 PM | 52 minutes ago |
| MACD: Buy Signal | Nov 3, 1:15 PM | 1 hour ago |
| SMA: Bearish | Nov 3, 11:15 AM | 3 hours ago |
| MACD: Sell Signal | Nov 3, 10:50 AM | 3 hours ago |
| SMA: Bullish | Nov 3, 10:40 AM | 3 hours ago |
| RSI: Overbought | Nov 3, 10:05 AM | 4 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 4 hours ago |
| SMA: Bullish | Nov 3, 9:30 AM | 4 hours ago |
| MACD: Buy Signal | Nov 3, 9:30 AM | 4 hours ago |
| MACD: Sell Signal | Nov 2, 3:40 PM | 22 hours ago |
| SMA: Bullish | Nov 2, 3:00 PM | 23 hours ago |
| MACD: Buy Signal | Nov 2, 2:35 PM | 23 hours ago |
| SMA: Bullish | Nov 2, 2:25 PM | 1 day ago |
| RSI: Oversold | Nov 2, 2:10 PM | 1 day ago |
| RSI: Oversold | Nov 2, 1:45 PM | 1 day ago |
| MACD: Sell Signal | Nov 2, 1:30 PM | 1 day ago |
| SMA: Bearish | Nov 2, 1:00 PM | 1 day ago |
| SMA: Bullish | Nov 2, 12:50 PM | 1 day ago |
| SMA: Bullish | Nov 2, 12:10 PM | 1 day ago |
| MACD: Buy Signal | Nov 2, 12:10 PM | 1 day ago |
Newest 20 of 72.
News
9 hours ago seekingalpha.com
Alvotech: The Market Is Still Pricing The Broken Factory
Alvotech is transitioning from supply remediation to throughput, with FDA-cleared facilities and multiple key biosimilar filings advancing toward decisions this quarter. ALVO's guidance implies a…
1 day ago globenewswire.com
Alvotech to Present at Upcoming Investor Conferences in November
REYKJAVIK, ICELAND (November 2, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients…
6 days ago globenewswire.com
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
REYKJAVIK, ICELAND (October 28, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for…
1 week ago zacks.com
New Strong Sell Stocks for October 21st
ALVO, CSIQ and AESI have been added to the Zacks Rank #5 (Strong Sell) List on October 21, 2026.
2 weeks ago globenewswire.com
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Enhanced process increases manufacturing productivity and frees up capacity to support growing demand across Alvotech's biosimilars portfolio
2 weeks ago globenewswire.com
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg
AVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg)
3 weeks ago defenseworld.net
Alvotech (NASDAQ:ALVO) Stock Has Consensus Target Price of $8.50 According to Brokerages
Shares of Alvotech (NASDAQ: ALVO - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are covering the firm, Marketbeat reports. One equities…
-
3 weeks ago benzinga.com
Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar Products
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New YorkStrategic long-term partnership to increase Alvotech’s global manufacturing…
3 weeks ago globenewswire.com
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
Collaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics' Syracuse facility in New York Strategic long-term partnership to increase Alvotech's global manufacturing…
-
4 weeks ago benzinga.com
Alvotech Gets FDA Nod For Added US Manufacturing Capacity For Humira Biosimilar SIMLANDI, Doubling Drug Substance Capacity At Reykjavik Site
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech’s two Reykjavik drug substance suitesFurther confirms resolution of FDA inspection-related…
4 weeks ago globenewswire.com
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech's biosimilar to Humira®
Approval enables AVT02 drug substance for U.S. commercial supply to be manufactured in either of Alvotech's two Reykjavik drug substance suites
1 month ago defenseworld.net
Alvotech (NASDAQ:ALVO) Receives $8.50 Average Target Price from Brokerages
Alvotech (NASDAQ: ALVO - Get Free Report) has been given an average rating of "Moderate Buy" by the eight analysts that are currently covering the firm, Marketbeat reports. One analyst has rated the…
1 month ago benzinga.com
LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On Wednesday
U.S. stocks mixed as Nasdaq rises; LuxExperience jumps 13.5% on strong sales, while Einride, Forgent, Cipher and others post gains.
1 month ago benzinga.com
Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For Wednesday
Analysts raised targets for RAPP, ALLR, UNP and ALVO; cut targets for NU, CLLS and JBHT, with several rating upgrades and downgrades.
1 month ago benzinga.com
This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday
Analysts upgraded Similarweb, Rocket Pharmaceuticals, Radiant Logistics and Ulta Beauty; Paychex rose to Peer Perform, with targets raised.
-
1 month ago benzinga.com
Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8
Barclays analyst Glen Santangelo upgrades Alvotech (NASDAQ:ALVO) from Underweight to Overweight and raises the price target from $4 to $8.
1 month ago seekingalpha.com
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Alvotech (ALVO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
1 month ago defenseworld.net
Financial Survey: Alvotech (NASDAQ:ALVO) & Alumis (NASDAQ:ALMS)
Alumis (NASDAQ: ALMS - Get Free Report) and Alvotech (NASDAQ: ALVO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies…
2 months ago globenewswire.com
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,…
2 months ago globenewswire.com
Alvotech to present at upcoming investor conferences in September
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients…
2 months ago benzinga.com
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Innovative Eyewear (NASDAQ:LUCY) stock rose 63.6% to $1.12 during Monday's regular session. The market value of their outstanding shares is at $5.8 million. Picard Medical (AMEX:PMI) shares…
2 months ago benzinga.com
Crude Oil Down 3%; XPeng Shares Fall After Q2 Results
US stocks traded mixed with the Dow Jones index gaining over 150 points. Consumer staples shares jumped while information technology stocks fell. XPeng Inc shares fell 7% due to wider than expected…
2 months ago benzinga.com
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
U.S. stocks were mixed, with the Dow Jones index gaining around 150 points on Monday.
2 months ago benzinga.com
Napco Security Technologies Posts Upbeat Q4 Results, Joins Alvotech, Rum Group And Other Big Stocks Moving Higher On Monday
The text discusses recent gains in the stock market, particularly for companies like Napco Security Technologies and SuperX AI Technology. US stocks were mixed, with the Dow Jones index gaining 150…
-
2 months ago benzinga.com
B of A Securities Initiates Coverage On Alvotech with Buy Rating, Announces Price Target of $7
B of A Securities analyst Jason Gerberry initiates coverage on Alvotech (NASDAQ:ALVO) with a Buy rating and announces Price Target of $7.
2 months ago globenewswire.com
Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets
REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for…
2 months ago seekingalpha.com
Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts
Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues,…
2 months ago seekingalpha.com
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
Alvotech (ALVO) Q2 2026 Earnings Call Transcript
2 months ago marketbeat.com
Alvotech Q2 Earnings Call Highlights
Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed…
2 months ago benzinga.com
Alvotech Q2 2026 Earnings Call Transcript
Alvotech (NASDAQ:ALVO) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This content is powered by…
2 months ago zacks.com
Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates
Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.
-
2 months ago benzinga.com
Alvotech Q2 EPS $(0.17) Misses $(0.04) Estimate, Sales $106.000M Miss $111.010M Estimate
Alvotech (NASDAQ:ALVO) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.04) by 325 percent. This is a 221.43 percent decrease over earnings of $0.14…
-
2 months ago benzinga.com
Alvotech Affirms FY2026 Sales Guidance of $650.000M-$700.000M vs $644.838M Est
Alvotech (NASDAQ:ALVO) affirms FY2026 sales outlook from $650.000 million-$700.000 million to $650.000 million-$700.000 million vs $644.838 million estimate.
3 months ago benzinga.com
AstraZeneca, GameStop, Snap And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures higher, AstraZeneca dips on merger talks, Apple down 7.4%, other stocks moving lower in pre-market trading.
3 months ago benzinga.com
Why Atkore Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving Premarket
Atkore Inc (ATKR) shares rise on strong Q3 results and acquisition by Prysmian for $95.00 per share. Other gainers include UPC, YYAI, RITR, FCUV, SGLY, FNGR, ALAR, FERG, and BMY while FMFC, PWCM,…
-
3 months ago benzinga.com
Alvotech Says FDA Closes Inspection Of Manufacturing Facility In Reykjavik, Iceland; FDA Confirms Inspection Classification Of Manufacturing Site Is Voluntary Action Indicated
Alvotech (NASDAQ:ALVO, ALVO-SDB))) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that…
-
4 months ago benzinga.com
Alvotech Strengthens Liquidity With $75M Term Loan, Building On Recent $165M Equity Raise For Total $240M In New Capital
— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management— Follows recent $165m equity raise strengthening cash position— Including equity financing…
4 months ago benzinga.com
Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings; other stocks declining in pre-market trading
4 months ago benzinga.com
Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket
HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open. Other gainers include SLBT, TDIC, IMCC, IVDA, NXTS, CRVO, PAVS, ALBT, and PURR. Losers include…
-
4 months ago benzinga.com
12 Health Care Stocks Moving In Monday's After-Market Session
12 Health Care Stocks Moving In Monday's After-Market Session
-
4 months ago benzinga.com
Alvotech Commences ~$125M Offering Of Ordinary Shares
Alvotech (NASDAQ:ALVO, ALVO-SDB))) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Wednesday's After-Market Session
12 Health Care Stocks Moving In Wednesday's After-Market Session
-
6 months ago benzinga.com
Alvotech Q1 Sales $105.900M Miss $140.847M Estimate
Alvotech (NASDAQ:ALVO) reported quarterly sales of $105.900 million which missed the analyst consensus estimate of $140.847 million by 24.81 percent. This is a 20.26 percent decrease over sales of…
-
6 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's After-Market Session
7 months ago benzinga.com
Mach Natural Resources, Mesoblast And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures down, Nasdaq 100 falls over 100 points. Mach Natural Resources LP (MNR) shares dip 7.6% in pre-market trading.
7 months ago benzinga.com
Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
Shares of nCino Inc (NASDAQ: NCNO) jumped 18% in pre-market trading after reporting strong Q4 results and issuing positive guidance for Q1 and FY27.
-
7 months ago benzinga.com
UBS Maintains Buy on Alvotech, Lowers Price Target to $6
UBS analyst Ashwani Verma maintains Alvotech (NASDAQ:ALVO) with a Buy and lowers the price target from $10 to $6.
-
7 months ago benzinga.com
Barclays Maintains Underweight on Alvotech, Lowers Price Target to $4
Barclays analyst Glen Santangelo maintains Alvotech (NASDAQ:ALVO) with a Underweight and lowers the price target from $5 to $4.
-
7 months ago benzinga.com
Alvotech Q4 Sales $173.200M Beat $159.927M Estimate
Alvotech (NASDAQ:ALVO) reported quarterly sales of $173.200 million which beat the analyst consensus estimate of $159.927 million by 8.30 percent. This is a 12.95 percent increase over sales of…